CVS Health announced that the company will undergo layoffs of 2,900 employees to cut costs.
According to a Reuters exclusive, CVS had been exploring options to reduce company costs via headcount initially, including fracturing the retail and pharmaceutical business to sell individually.
The company recently announced a quarterly dividend “of sixty-six and one-half cents ($0.665 cents) per share on the Common Stock of the Corporation. The dividend is payable on November 1, 2024, to holders of record on October 21, 2024.”
CVS is looking at cutting costs
Glenview Capital Management is involved with a household name in pharmacy and healthcare, and according to Reuters, it is engaged in private dialogue to strengthen its operating performance.
The hedge fund is taking forward “constructive conversations” to size down the healthcare provider and is pivotal in the decision to cut these 2,900 employee’s jobs.
This equates to 1% of the nationally known pharmacy brand’s overall workforce. In August of this year, CVS announced a 2 billion dollar cost reduction exercise, hot on the heels of the company’s second quarter 2024 results.
Karen S. Lynch, CVS Health President and CEO’s statement at that time was geared toward the future. Saying “We have many points of differentiation that position us to win now and into the future. Our innovation is accelerating more transparent pharmacy reimbursement models, increasing the use of biosimilars, and providing better patient outcomes through our connected healthcare delivery assets. Our integrated model and our strategy are enabling us to execute in a challenging environment and we are delivering the value our customers demand. We are taking action today to ensure we make the most of our many opportunities, including leadership changes in the Health Care Benefits segment.”
Over 5,000 non-customer-facing roles were removed from the company last year as part of existing $496 million restructuring and cost-reduction measures.
Image: Pexels.
The post CVS Health announces cost-cutting layoffs appeared first on Due.
Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
